期刊
JOURNAL OF NEUROTRAUMA
卷 38, 期 13, 页码 1762-1782出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/neu.2020.7259
关键词
biomarkers; concussion; diffusion tensor imaging; molecular assays; traumatic brain injury
资金
- DHA Contracting Office (CO-NCR) [HT0014-19-C-0004, HT0014]
In the past 20 years, new technologies have significantly improved the diagnosis and prognosis of traumatic brain injury (TBI). Researchers are now focusing on identifying biomarkers to detect and monitor the condition, with particular attention on advancements in biomolecular and neuroimaging domains. Integration of these technologies could lead to improved disease prognostication and patient care.
The last 20 years have seen the advent of new technologies that enhance the diagnosis and prognosis of traumatic brain injury (TBI). There is recognition that TBI affects the brain beyond initial injury, in some cases inciting a progressive neuropathology that leads to chronic impairments. Medical researchers are now searching for biomarkers to detect and monitor this condition. Perhaps the most promising developments are in the biomolecular and neuroimaging domains. Molecular assays can identify proteins indicative of neuronal injury and/or degeneration. Diffusion imaging now allows sensitive evaluations of the brain's cellular microstructure. As the pace of discovery accelerates, it is important to survey the research landscape and identify promising avenues of investigation. In this review, we discuss the potential of molecular and diffusion tensor imaging (DTI) biomarkers in TBI research. Integration of these technologies could advance models of disease prognosis, ultimately improving care. To date, however, few studies have explored relationships between molecular and DTI variables in patients with TBI. Here, we provide a short primer on each technology, review the latest research, and discuss how these biomarkers may be incorporated in future studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据